Talukder A H, Vadlamudi R, Mandal M, Kumar R
The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Cancer Res. 2000 Jan 15;60(2):276-81.
Heregulin beta1 (HRG), a combinatorial ligand for human epidermal growth factor receptor 3 and human epidermal growth factor receptor 4 receptors, is a regulatory secretory polypeptide with distinct biological effects such as growth stimulation, differentiation, invasiveness, and migration in breast cancer cells. The mechanism underlying the diverse functions of HRG is not well established, but it is believed to be dependent on the induced changes in expression of specific cellular gene products, their modification, or both. The binding of basic leucine zipper transcription factors to the cAMP response element is known to activate a variety of gene products with a role or roles in growth regulation. In the studies presented here, we identified basic leucine zipper activating transcription factor (ATF) 4 as one of the HRG-inducible gene product. We demonstrated that HRG stimulation of human cancer cells induces expression of ATF4 mRNA and protein, ATF4 DNA binding activity, and ATF4 transactivating function. Consistent with its role as a transcriptional activator, HRG-stimulated ATF4 protein stimulated the transcription from an artificial promoter with three tandem ATF sites or from a naturally occurring promoter with ATF4 sites such as E-selectin. We also demonstrated a preferential role of the HRG-stimulated mitogen-activated protein kinase pathway, but not the phosphatidylinositol 3'-kinase pathway, in supporting the observed increase in ATF4 DNA binding activity and transcription from E-selectin promoter in HRG-stimulated cells. Because ATF4 binding sites are present in a variety of growth-regulating cellular genes, these findings suggest that the stimulation of ATF4 expression and its transactivating functions may constitute an important mechanism of HRG-mediated regulation of putative genes with diversified functions. The present study is the first demonstration of regulation of expression and transactivation ability of ATF4 by any polypeptide growth factor.
Heregulin beta1(HRG)是一种针对人表皮生长因子受体3和人表皮生长因子受体4的组合配体,是一种调节性分泌多肽,在乳腺癌细胞中具有不同的生物学效应,如生长刺激、分化、侵袭和迁移。HRG多种功能背后的机制尚未完全明确,但据信它依赖于特定细胞基因产物表达的诱导性变化、它们的修饰或两者兼而有之。已知碱性亮氨酸拉链转录因子与cAMP反应元件的结合可激活多种在生长调节中起作用的基因产物。在本研究中,我们确定碱性亮氨酸拉链激活转录因子(ATF)4是HRG诱导的基因产物之一。我们证明,HRG对人癌细胞的刺激可诱导ATF4 mRNA和蛋白质的表达、ATF4的DNA结合活性以及ATF4的反式激活功能。与其作为转录激活因子的作用一致,HRG刺激的ATF4蛋白可刺激来自具有三个串联ATF位点的人工启动子或来自具有ATF4位点(如E-选择素)的天然启动子的转录。我们还证明,在支持HRG刺激的细胞中观察到的ATF4 DNA结合活性增加和从E-选择素启动子的转录方面,HRG刺激的丝裂原活化蛋白激酶途径而非磷脂酰肌醇3'-激酶途径具有优先作用。由于ATF4结合位点存在于多种生长调节细胞基因中,这些发现表明,ATF4表达及其反式激活功能的刺激可能构成HRG介导的对具有多种功能的假定基因进行调节的重要机制。本研究首次证明了任何多肽生长因子对ATF4表达和反式激活能力的调节。